Instrument Inactif

Communiqués Viralytics Ltd. Other OTC

Actions

Recherche biotechnologique et médicale

Communiqués

28/11/17	Viralytics : Chairman’s letter to shareholders	PU
12/11/17	Viralytics : New Data Presented at SITC Annual Meeting	PU
18/08/17	Viralytics : Annual Report and Full Year Financial Results	PU
28/06/17	Viralytics : Newsletter	PU
28/06/17	Viralytics : Positive Bio-Marker Data from CANON Study	PU
06/06/17	Viralytics : Update on MITCI and KEYNOTE 200 trials at ASCO Ann Meeting	PU
05/04/17	Viralytics : Progress in the CAVATAK® and KEYTRUDA® Combination KEYNOTE-200 clinical trial	PU
05/04/17	Viralytics : CAVATAK® in Combination with YERVOY® Provides Promising Results in Advanced Melanoma from the Phase 1b MITCI clinical study	PU
04/04/17	Viralytics : Promising Results in CAPRA Trial of CAVATAK® in Combination with KEYTRUDA® in Melanoma Patients	PU
09/03/17	Viralytics : Edison Report – Cavatak combo data at AACR next month	PU
02/03/17	Viralytics : ASX Release – Viralytics to Present New CAVATAK Clinical Data at American Association for Cancer Research Annual Meeting 2017	PU
16/02/17	Viralytics : Receives $4.3 Million R&D Tax Incentive	PU
14/11/16	Viralytics : Promising Advanced Melanoma Results from KEYTRUDA Combination Trial announced at SITC	PU
06/06/16	Viralytics : Dr Malcolm McColl on ABC TV's The Business	PU
10/05/16	Edison: Eye-catching MITCI Data	PU
21/04/16	Viralytics : Further Promising Data at AACR Meeting	PU
17/03/16	Viralytics : Clinical Results at Two Major Conferences	PU
21/12/15	Viralytics : Bioshares Top Six Stock Picks for 2016	PU
16/12/15	Viralytics : Completes $28 million Placement – SPP to Followm	PU
30/06/15	Viralytics : on ABC TV ''The Business''	PU
18/06/15	Viralytics : ROTH Capital Partners - Updated Research Note	PU
10/06/15	Viralytics : to Present Initial Bladder Cancer Results at Oncolytic Virus Conference	PU
02/06/15	Viralytics : Positive final results from CAVATAK Phase 2 Melanoma Trial	PU
06/05/15	Viralytics : FDA Advisory Vote on Amgen’s T-Vec a Positive for Viralytics	PU
01/05/15	Viralytics : Boost for Oncolytic Viruses - Amgen''s T-Vec Approved by FDA Advisory Committee	PU